Tiziana Life Sciences Ltd (TLSA)
Tiziana Life Sciences develops antibody therapies for neurodegenerative and neuroinflammatory diseases from its base in London. It last closed at $0.62 on Nov 20, down 8.14% on the day. Over the last 12 months TLSA insiders bought $986K of stock on the open market and sold $0, according to SEC Form 4 filings.
Key Stats
Fiscal 2024Not reported for this period.
From TLSA's SEC filings, latest 20-F for the period ending Dec 31, 2024 (filed May 1). Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on TLSA
Technical AnalysisPrices may be delayed
The stock is 14% below its 20 day and 44% below its 50 day average. It is 85% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot S1 at $0.59, and the nearest resistance the Pivot at $0.64.
| RSI (14) | 40.35 | Middle of its range | Neutral |
| MACD | -0.08 | Above its signal line | Bullish |
| Stochastic | 45.2 | Middle of its range | Neutral |
| ADX (14) | 30.2 | Trending down | |
| Williams %R | -75.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -51.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −9.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.10 | Typical daily range, 15.3% of price |
| RSI (14) | 34.42 | Weak, oversold below 30 | Neutral |
| MACD | -0.15 | Below its signal line | Bearish |
| Stochastic | 9.5 | Near the bottom of its range | Oversold |
| ADX (14) | 13.6 | No clear trend | |
| Williams %R | -90.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -169.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −35.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.22 | Typical daily range, 35.3% of price |
What happened before
See how TLSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How TLSA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options FlowPrices may be delayed
90DNo whale options trades in TLSA in the last 90 days.
TLSA Institutional Ownership
Full report →- ▲16 buying vs 12 selling
- ▲Shares held by funds +65.0%
- ▲Funds holding +4
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 36 | 32 | +12.5% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 7 / 9 | 6 / 7 | +23.1% |
| Reduced / sold out | 9 / 3 | 4 / 7 | +9.1% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
TLSA Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 5 | Ivor ElrifiCEO | Buy | 321,423 | $0.99 | $319K |
| Aug 3 | Ivor ElrifiCEO | Buy | 667,000 | $1.00 | $667K |
From SEC Form 4 filings by TLSA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TLSA is in one of them and how their past TLSA trades turned out.
TLSA News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TLSA in an article yet. Here's the latest on the wider market.
- Tiziana Life Sciences Ltd Press Release, Dated November 12, 2026
- Tiziana Life Sciences Ltd Press Release, Dated November 9, 2026
- Tiziana Life Sciences Ltd Press Release, Dated November 9, 2026
- Tiziana Life Sciences Ltd Press Release, Dated November 5, 2026
- Tiziana Life Sciences Ltd Press Release, Dated November 2, 2026
- Tiziana Life Sciences Ltd Press Release, Dated October 21, 2026
About Tiziana Life Sciences
Tiziana Life Sciences is a biotechnology company based in London, England, that develops treatments for neurodegenerative and neuroinflammatory diseases. Its main candidate, Foralumab, is an antibody being tested as a nasal treatment for conditions such as secondary progressive multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. The company is focused on these clinical programs and aims its work at patients with these conditions.
- Headquarters
- London, England, United Kingdom

